Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GST-HG181
- Development stage
- Unknown
- Lead developer
- Fujian Akeylink Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GST-HG181 is an investigational small molecule 3C-like protease (3CLpro) inhibitor developed by Fujian Akeylink Biotechnology for the treatment of COVID-19. It is specifically designed as a single-agent therapy that does not require pharmacokinetic boosting with Ritonavir, a feature that distinguishes it from other protease inhibitors like Paxlovid or Akeylink's own Tazovid. By targeting the 3CL protease (also known as the main protease or Mpro), which is essential for the cleavage of viral polyproteins into functional units, GST-HG181 effectively halts SARS-CoV-2 replication. The drug is currently in Phase 1 clinical development.
02
Targets
Mpro (3C-like proteinase of SARS-CoV-2)
Beyond the preview
Go deeper on GST-HG181.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GST-HG181.